Markowitz, M <br/><br/>
A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection.  [electronic resource] 

 -  The Journal of infectious diseases  Jun 1998 
 - 1533-40 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0022-1899 
<br/><br/><label>Standard No.: </label>10.1086/515312  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anti-HIV Agents--adverse effects<br/>CD4 Lymphocyte Count<br/>Drug Evaluation<br/>Drug Resistance, Microbial<br/>Female<br/>Follow-Up Studies<br/>HIV Infections--drug therapy<br/>HIV Protease Inhibitors--adverse effects<br/>HIV-1--drug effects<br/>Humans<br/>Male<br/>Nelfinavir--adverse effects<br/>RNA, Viral